217 related articles for article (PubMed ID: 37043203)
1. Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
Belcher AM; Cole TO; Massey E; Billing AS; Wagner M; Wooten W; Epstein DH; Hoag SW; Wickwire EM; Greenblatt AD; Colloca L; Rotrosen J; Magder L; Weintraub E; Wish ED; Kaptchuk TJ
JAMA Netw Open; 2023 Apr; 6(4):e237099. PubMed ID: 37043203
[TBL] [Abstract][Full Text] [Related]
2. Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment.
Belcher AM; Cole TO; Greenblatt AD; Hoag SW; Epstein DH; Wagner M; Billing AS; Massey E; Hamilton KR; Kozak ZK; Welsh CJ; Weintraub E; Wickwire EM; Wish ED; Kaptchuk TJ; Colloca L
BMJ Open; 2019 Jun; 9(6):e026604. PubMed ID: 31230007
[TBL] [Abstract][Full Text] [Related]
3. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial.
Ware OD; Sweeney MM; Cunningham C; Umbricht A; Stitzer M; Dunn KE
JAMA Netw Open; 2023 Mar; 6(3):e232278. PubMed ID: 36920397
[TBL] [Abstract][Full Text] [Related]
4. Telehealth Mindfulness-Oriented Recovery Enhancement vs Usual Care in Individuals With Opioid Use Disorder and Pain: A Randomized Clinical Trial.
Cooperman NA; Lu SE; Hanley AW; Puvananayagam T; Dooley-Budsock P; Kline A; Garland EL
JAMA Psychiatry; 2024 Apr; 81(4):338-346. PubMed ID: 38061786
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Supervised dosing with a long-acting opioid medication in the management of opioid dependence.
Saulle R; Vecchi S; Gowing L
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766
[TBL] [Abstract][Full Text] [Related]
7. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial.
Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME;
Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
9. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.
Hser YI; Saxon AJ; Huang D; Hasson A; Thomas C; Hillhouse M; Jacobs P; Teruya C; McLaughlin P; Wiest K; Cohen A; Ling W
Addiction; 2014 Jan; 109(1):79-87. PubMed ID: 23961726
[TBL] [Abstract][Full Text] [Related]
10. A pilot randomized clinical trial of mindfulness-oriented recovery enhancement as an adjunct to methadone treatment for people with opioid use disorder and chronic pain: Impact on illicit drug use, health, and well-being.
Cooperman NA; Hanley AW; Kline A; Garland EL
J Subst Abuse Treat; 2021 Aug; 127():108468. PubMed ID: 34134880
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Safety and Efficacy of Methadone vs Morphine for Treatment of Neonatal Abstinence Syndrome: A Randomized Clinical Trial.
Davis JM; Shenberger J; Terrin N; Breeze JL; Hudak M; Wachman EM; Marro P; Oliveira EL; Harvey-Wilkes K; Czynski A; Engelhardt B; D'Apolito K; Bogen D; Lester B
JAMA Pediatr; 2018 Aug; 172(8):741-748. PubMed ID: 29913015
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
13. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of methadone treatment of arrestees: 24-month post-release outcomes.
Schwartz RP; Kelly SM; Mitchell SG; O'Grady KE; Duren T; Sharma A; Gryczynski J; Jaffe JH
Drug Alcohol Depend; 2021 Jan; 218():108392. PubMed ID: 33187759
[TBL] [Abstract][Full Text] [Related]
15. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial.
Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S
JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025
[TBL] [Abstract][Full Text] [Related]
16. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
17. Extended-release pharmacotherapy for opioid use disorder (EXPO): protocol for an open-label randomised controlled trial of the effectiveness and cost-effectiveness of injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone.
Marsden J; Kelleher M; Hoare Z; Hughes D; Bisla J; Cape A; Cowden F; Day E; Dewhurst J; Evans R; Hearn A; Kelly J; Lowry N; McCusker M; Murphy C; Murray R; Myton T; Quarshie S; Scott G; Turner S; Vanderwaal R; Wareham A; Gilvarry E; Mitcheson L
Trials; 2022 Aug; 23(1):697. PubMed ID: 35986418
[TBL] [Abstract][Full Text] [Related]
18. FORWARDS-1: an adaptive, single-blind, placebo-controlled ascending dose study of acute baclofen on safety parameters in opioid dependence during methadone-maintenance treatment-a pharmacokinetic-pharmacodynamic study.
Paterson LM; Barker D; Cro S; Mozgunov P; Phillips R; Smith C; Nahar L; Paterson S; Lingford-Hughes AR
Trials; 2022 Oct; 23(1):880. PubMed ID: 36258248
[TBL] [Abstract][Full Text] [Related]
19. Effect of Open-label Placebo on Children and Adolescents With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Clinical Trial.
Nurko S; Saps M; Kossowsky J; Zion SR; Di Lorenzo C; Vaz K; Hawthorne K; Wu R; Ciciora S; Rosen JM; Kaptchuk TJ; Kelley JM
JAMA Pediatr; 2022 Apr; 176(4):349-356. PubMed ID: 35099543
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
